NCT01533935 - Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. | Biotech Hunter

Enrollment

291

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo

placebo matching tiotropium + olodaterol

DRUG

Tiotropium + Olodaterol

Tiotropium 2.5 mcg + olodaterol 5 mcg once daily

DRUG

tiotropium + Olodaterol

tiotropium 5 mcg + olodaterol 5 mcg once daily

DRUG

Tiotropium

tiotropium

DRUG

Olodaterol

Olodaterol 5 mcg once daily

DEVICE

Respimat

Respimat inhaler

Trial Locations (33)

Unknown

1237.14.01404 Boehringer Ingelheim Investigational Site, Phoenix

1237.14.01414 Boehringer Ingelheim Investigational Site, Austell

1237.14.01417 Boehringer Ingelheim Investigational Site, Baltimore

1237.14.01418 Boehringer Ingelheim Investigational Site, Rochester

1237.14.01408 Boehringer Ingelheim Investigational Site, Saint Charles

1237.14.01409 Boehringer Ingelheim Investigational Site, Charlotte

1237.14.01407 Boehringer Ingelheim Investigational Site, Greenville

1237.14.01403 Boehringer Ingelheim Investigational Site, Spartanburg

1237.14.01401 Boehringer Ingelheim Investigational Site, Union

1237.14.01412 Boehringer Ingelheim Investigational Site, Dallas

1237.14.01410 Boehringer Ingelheim Investigational Site, Seattle

1237.14.54402 Boehringer Ingelheim Investigational Site, Buenos Aires

1237.14.54401 Boehringer Ingelheim Investigational Site, Mendoza

1237.14.43402 Boehringer Ingelheim Investigational Site, Grieskirchen

1237.14.43401 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee

1237.14.11404 Boehringer Ingelheim Investigational Site, Vancouver

1237.14.11403 Boehringer Ingelheim Investigational Site, Toronto

1237.14.11402 Boehringer Ingelheim Investigational Site, Montreal

1237.14.11401 Boehringer Ingelheim Investigational Site, Ste-Foy

1237.14.49406 Boehringer Ingelheim Investigational Site, Bamberg

1237.14.49404 Boehringer Ingelheim Investigational Site, Bochum

1237.14.49401 Boehringer Ingelheim Investigational Site, Großhansdorf

1237.14.49405 Boehringer Ingelheim Investigational Site, Hamburg

1237.14.49403 Boehringer Ingelheim Investigational Site, Hanover

1237.14.49402 Boehringer Ingelheim Investigational Site, Kiel

1237.14.31001 Boehringer Ingelheim Investigational Site, Heerlen

1237.14.31005 Boehringer Ingelheim Investigational Site, Hoofddorp

1237.14.31004 Boehringer Ingelheim Investigational Site, Hoorn

1237.14.31006 Medisch Centrum Leeuwarden, Leeuwarden

1237.14.31007 Boehringer Ingelheim Investigational Site, Leiden

1237.14.70401 Boehringer Ingelheim Investigational Site, Moscow

1237.14.70402 Boehringer Ingelheim Investigational Site, Saint Petersburg

1237.14.46001 Boehringer Ingelheim Investigational Site, Lund